Table 2 Targeted agents against TIM-3
From: Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting
type | products | mechanism | phase | disease or cell line | reference |
|---|---|---|---|---|---|
Anti-TIM-3 antibody | sabatolimab (MBG453) | reverse T-cell exhaustion and anti-myeloid leukemia cell proliferation | Clinical Ib | vHR/HR-MDS, ND-AML | Brunner AM, et al. Blood. 2021 |
Clinical II | IR/HR/vHR-MDS | Zeidan AM, et al. Blood. 2022 | |||
Clinical III | IR/vHR/HR-MDS, CMML | Santini V, et al. Blood. 2022 | |||
TIM-3-CD28 fusion proteins | TIM-3/CD28-5 and TIM-3/CD28-6 | increase proliferation of CAR-T cells, enhance cytokine secretion, proliferation of T cell | preclinical | K562 cell line | Blaeschke F, et al. Front Immunol. 2022 |
TIM-3-CAR-T cells | T3/28-CD19-CAR-T cells | enhance CAR-T cytotoxicity, cytokine secretion and persistence | preclinical | B-cell lymphoma | Zhao S, et al. J Immunother Cancer. 2021 |
Anti-TIM-3 CAR-T cells | eradicate primary TIM-3 + CD34 + LSCs and sparing the TIM-3-CD34 + cells | preclinical | AML | Lee WS, et al. Mol Cancer Ther. 2021 | |
Anti-GAL-9 antibody | aGal-9 antibody | reverse T-cell exhaustion | preclinical | CLL | Llaó Cid L, et al. Blood. 2022 |
LYT-200 | increase the ability to kill leukemia cells | preclinical | B/T-ALL, AML and DLBCL | Henry CJ, et al. Blood. 2022 |